Showing results (51-60 of 331) with videos related to
Sort By:
Pageof 34
Expert Opinion on Emerging Drugs|May 6, 2016
Emerging targeted therapies for melanomaDouglas B Johnson, Megan H Pollack, Jeffrey A SosmanBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 25, 2020
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin CancerJames Randall Patrinely, Anna K Dewan, Douglas B JohnsonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2023
Corticosteroids and Cancer ImmunotherapyRachel S Goodman, Douglas B Johnson, Justin M BalkoSeminars in Cancer Biology|September 18, 2017
Emerging biomarkers for cancer immunotherapy in melanomaMargaret L Axelrod, Douglas B Johnson, Justin M BalkoCancer Journal (Sudbury, Mass.)|January 24, 2018
Toxicities Associated With PD-1/PD-L1 BlockadeDaniel Y Wang, Douglas B Johnson, Elizabeth J DavisCancer|February 28, 2017
Immune checkpoint inhibitors in challenging populationsDouglas B Johnson, Ryan J Sullivan, Alexander M MenziesNature Reviews. Endocrinology|April 20, 2021
Endocrine toxicities of immune checkpoint inhibitorsJordan J Wright, Alvin C Powers, Douglas B JohnsonCurrent Oncology Reports|May 9, 2019
Immunotherapy in Older Adults with CancerRichard Curtis Godby, Douglas B Johnson, Grant R WilliamsOncology (Williston Park, N.Y.)|April 24, 2018
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune DiseaseDouglas B Johnson, Kathryn E Beckermann, Daniel Y WangCurrent Oncology Reports|January 9, 2016
Molecular Targeted Therapy Approaches for BRAF Wild-Type MelanomaRomany A N Johnpulle, Douglas B Johnson, Jeffrey A SosmanPageof 34